Jingsong Zhang
Moffitt Cancer Center · The First Affiliated Hospital with Nanjing Medical University · H. Lee Moffitt Cancer Center and Research Institute
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Jingsong Zhang as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 08:31 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07476001 · Phase 2a Study of High-Dose Testosterone Followed by Radioligand Therapy in mCRPCH. Lee Moffitt Cancer Center and Research Institute · recruiting · Metastatic Castration-resistant Prostate Cancer · principal investigator
- Ph2NCT06734130 · Adaptive Androgen Deprivation and Docetaxel in Metastatic Castration Sensitive Prostate CancerH. Lee Moffitt Cancer Center and Research Institute · active not recruiting · Metastatic Castration Sensitive Prostate Cancer · principal investigator
- Ph1NCT06193486 · Autologous Gamma Delta T Cells to Target Prostate Stem Cell Antigen in mCRPCH. Lee Moffitt Cancer Center and Research Institute · recruiting · Metastatic Castration-resistant Prostate Cancer · principal investigator
- Ph2NCT05751941 · Study of Sipuleucel-T With or Without Continuing New Hormonal Agents in Metastatic Prostate CancerH. Lee Moffitt Cancer Center and Research Institute · active not recruiting · Prostate Cancer, Metastatic Prostate Cancer · principal investigator
- N/ANCT05215457 · Severity Indices of Diquat Poisoning for Triage and Prognosis in Acute Diquat PoisoningThe First Affiliated Hospital with Nanjing Medical University · completed · Diquat Poisoning · study chair
- Ph2NCT05189457 · First Strike, Second Strike Therapies for High Risk Metastatic Castration Sensitive Prostate CancerH. Lee Moffitt Cancer Center and Research Institute · active not recruiting · Prostate Cancer, Stage IV Prostate Cancer · principal investigator
- N/ANCT05035797 · CaRe-ECMO Program on ECMO WeaningThe First Affiliated Hospital with Nanjing Medical University · unknown · Critical Illness · principal investigator
- N/ANCT04964310 · Screening of Susceptibility Genes for APAP Induced Drug Induced LIver Injury in ChiNese Population: a Case-control StudyThe First Affiliated Hospital with Nanjing Medical University · recruiting · Acetaminophen, Drug-Induced Liver Injury, Pharmacogenetics · study chair
- N/ANCT04343365 · Generating Novel Therapeutic Strategies Based on Evolutionary Tumor BoardH. Lee Moffitt Cancer Center and Research Institute · recruiting · Incurable Disease · principal investigator
- Early Ph1NCT03511196 · Intermittent Androgen Deprivation Therapy for Stage IV Castration Sensitive Prostate CancerH. Lee Moffitt Cancer Center and Research Institute · active not recruiting · Prostate Cancer, Stage IV Prostate Cancer, Advanced Prostate Cancer · principal investigator
- N/ANCT02981797 · Assess Gamma H2AX Positivity in Circulating Prostate Cancer Cells Before and After Radium 223H. Lee Moffitt Cancer Center and Research Institute · completed · Prostate Cancer, Prostate Adenocarcinoma · principal investigator
- Ph2NCT02901548 · Phase 2 Durvalumab (Medi4736) for Bacillus Calmette-Guérin (BCG) Refactory Urothelial Carcinoma in Situ of the BladderH. Lee Moffitt Cancer Center and Research Institute · terminated · Carcinoma in Situ of Bladder, Bladder Cancer · principal investigator
- Early Ph1NCT02415621 · Adaptive Abiraterone Therapy for Metastatic Castration Resistant Prostate CancerH. Lee Moffitt Cancer Center and Research Institute · completed · Prostate Cancer · principal investigator
- Ph1NCT02300610 · Enzalutamide in Combination With Gemcitabine and Cisplatin in Bladder CancerH. Lee Moffitt Cancer Center and Research Institute · completed · Bladder Cancer, Carcinoma, Transitional Cell, Renal Pelvis Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 08:31 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 08:31 UTC. The ranking covers the 200 most relevant of 4271 PubMed records, and a shared surname and initials can bring in a namesake. All 4271 on PubMed
- 163 citationsRCR 33.1
- 47 citationsRCR 7.3
- Adjuvant nivolumab versus placebo for high-risk muscle-invasive urothelial carcinoma: 5-year efficacy and ctDNA results from CheckMate 274.Ann Oncol · 202645 citationsRCR 22.5
- Final analysis of nivolumab plus cabozantinib for advanced renal cell carcinoma from the randomized phase III CheckMate 9ER trial.Ann Oncol · 202637 citationsRCR 18.5
- 31 citationsRCR 8.0
- Intensive vs Conventional Intraoperative Blood Pressure Management on Cardiovascular Events After Major Abdominal Surgery: The BP-CARES Randomized Trial.J Am Coll Cardiol · 202530 citationsRCR 13.9
- Ivarmacitinib for Moderate to Severe Atopic Dermatitis in Adults and Adolescents: A Phase 3 Randomized Clinical Trial.JAMA Dermatol · 202524 citationsRCR 7.3
- Probiotic-induced enrichment of Adlercreutzia equolifaciens increases gut microbiome wellness index and maps to lower host blood glucose levels.Gut Microbes · 202524 citationsRCR 7.4
- Lazertinib Versus Osimertinib in Previously Untreated EGFR-Mutant Advanced NSCLC: A Randomized, Double-Blind, Exploratory Analysis From MARIPOSA.J Thorac Oncol · 202522 citationsRCR 4.3
- 22 citationsRCR 11.0